OTCMNYMXF
Market cap9mUSD
Dec 31, Last price
0.10USD
1D
0.00%
1Q
-16.67%
Jan 2017
-96.25%
Name
Nymox Pharmaceutical Corp
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
8.68%
Rev. gr., 5y
-55.20%
Revenues
0k
Net income
-9m
L+34.49%
CFO
-4m
L-22.06%
Earnings
Aug 28, 2025
Profile
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 3,994 | 6,652 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (3,994) | (6,652) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | (433) | (1) | ||||||
Tax Rate | ||||||||
NOPAT | (3,561) | (6,652) | ||||||
Net income | (8,844) 34.49% | (6,576) -47.55% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 1,150 | 6,007 | ||||||
BB yield | -2.13% | -20.79% | ||||||
| Debt | ||||||||
Debt current | 750 | 173 | ||||||
Long-term debt | 173 | |||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | 680 | (1,057) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (4,057) | (5,205) | ||||||
CAPEX | (3) | |||||||
Cash from investing activities | (3) | |||||||
Cash from financing activities | 2,727 | 5,778 | ||||||
FCF | (1,447) | (6,458) | ||||||
| Balance | ||||||||
Cash | 70 | 1,403 | ||||||
Long term investments | ||||||||
Excess cash | 70 | 1,403 | ||||||
Stockholders' equity | (34,166) | (27,467) | ||||||
Invested Capital | 31,743 | 27,158 | ||||||
ROIC | ||||||||
ROCE | 164.84% | 2,152.75% | ||||||
| EV | ||||||||
Common stock shares outstanding | 91,687 | 89,383 | ||||||
Price | 0.59 82.49% | 0.32 -75.13% | ||||||
Market cap | 54,096 87.20% | 28,897 -72.88% | ||||||
EV | 54,776 | 27,840 | ||||||
EBITDA | (3,825) | (6,640) | ||||||
EV/EBITDA | ||||||||
Interest | 61 | 43 | ||||||
Interest/NOPBT | ||||||||